1. Pink Sheet

Generic Drug User Fee Program Sees First-Ever Fee Spending Decrease, FTE Decline

 
• By Derrick Gingery

Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.

A toy train pulling a cargo of money This picture could be a reference to 'money delivery', gravy train, cargo, freight. Also, money supply and transferring money or wiring money.
Overall GDUFA spending increased in FY 2019, but user fee revenue spending did not. • Source: Shutterstock

Add financial and personnel firsts to the record-breaking fiscal year 2019 performance of the US Food and Drug Administration’s generic drug user fee program.

FDA officials touted the new all-time high ANDA approval and tentative approval total set that year in the opening of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

More from Pathways & Standards

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.